These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 36330098)

  • 1. Cost-effectiveness of edaravone dexborneol versus edaravone for the treatment of acute ischemic stroke in China: Based on the TASTE study.
    Shi F; He Z; Wang L; Su H; Han S
    Front Pharmacol; 2022; 13():938239. PubMed ID: 36330098
    [No Abstract]   [Full Text] [Related]  

  • 2. Cost-effectiveness of edaravone dexborneol versus dl-3-n-butylphthalide for the treatment of acute ischemic stroke: a Chinese health care perspective.
    Li J; Cao W; Zhao F; Jin P
    BMC Public Health; 2024 Feb; 24(1):436. PubMed ID: 38347500
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of edaravone dexborneol versus human urinary kallidinogenase for acute ischemic stroke in China.
    Chen P; Luo M; Chen Y; Zhang Y; Wang C; Li H
    Health Econ Rev; 2024 Jan; 14(1):7. PubMed ID: 38285185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Edaravone Dexborneol Versus Edaravone Alone for the Treatment of Acute Ischemic Stroke: A Phase III, Randomized, Double-Blind, Comparative Trial.
    Xu J; Wang A; Meng X; Yalkun G; Xu A; Gao Z; Chen H; Ji Y; Xu J; Geng D; Zhu R; Liu B; Dong A; Mu H; Lu Z; Li S; Zheng H; Chen X; Wang Y; Zhao X; Wang Y;
    Stroke; 2021 Mar; 52(3):772-780. PubMed ID: 33588596
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sublingual Edaravone Dexborneol for the Treatment of Acute Ischemic Stroke: The TASTE-SL Randomized Clinical Trial.
    Fu Y; Wang A; Tang R; Li S; Tian X; Xia X; Ren J; Yang S; Chen R; Zhu S; Feng X; Yao J; Wei Y; Dong X; Ling Y; Yi F; Deng Q; Guo C; Sui Y; Han S; Wen G; Li C; Dong A; Sun X; Wang Z; Shi X; Liu B; Fan D
    JAMA Neurol; 2024 Feb; 81(4):319-26. PubMed ID: 38372981
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of edaravone dexborneol on functional outcome and inflammatory response in patients with acute ischemic stroke.
    Chen W; Zhang H; Li Z; Deng Q; Wang M; Chen Y; Zhang Y
    BMC Neurol; 2024 Jun; 24(1):209. PubMed ID: 38902691
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of Edaravone Dexborneol versus edaravone for patients with acute ischaemic stroke: a phase II, multicentre, randomised, double-blind, multiple-dose, active-controlled clinical trial.
    Xu J; Wang Y; Wang A; Gao Z; Gao X; Chen H; Zhou J; Zhao X; Wang Y
    Stroke Vasc Neurol; 2019 Sep; 4(3):109-114. PubMed ID: 31709115
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rationale and design of Treatment of Acute Ischaemic Stroke with Edaravone Dexborneol II (TASTE-2): a multicentre randomised controlled trial.
    Wang C; Gu HQ; Dong Q; Xu A; Wang N; Yang Y; Wang F; Wang Y
    Stroke Vasc Neurol; 2024 Mar; ():. PubMed ID: 38471696
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of thrombolysis within 4.5 hours of acute ischemic stroke in China.
    Pan Y; Chen Q; Zhao X; Liao X; Wang C; Du W; Liu G; Liu L; Wang C; Wang Y; Wang Y;
    PLoS One; 2014; 9(10):e110525. PubMed ID: 25329637
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of tirofiban for acute ischemic stroke without large or medium-sized vessel occlusion: A Markov modelling analysis from the Chinese and United States perspectives.
    Wang L; Zeng Y; Zhou L; Xu P; Guo X; Xie Y; Cai J; Pan M; Tang J; Gong Q; Su R; Liu Y; Lou Y
    PLoS One; 2024; 19(2):e0297939. PubMed ID: 38363737
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model.
    Fox M; Mealing S; Anderson R; Dean J; Stein K; Price A; Taylor RS
    Health Technol Assess; 2007 Nov; 11(47):iii-iv, ix-248. PubMed ID: 17999842
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Edaravone Dexborneol Treatment Attenuates Neuronal Apoptosis and Improves Neurological Function by Suppressing 4-HNE-Associated Oxidative Stress After Subarachnoid Hemorrhage.
    Chen Q; Cai Y; Zhu X; Wang J; Gao F; Yang M; Mao L; Zhang Z; Sun B
    Front Pharmacol; 2022; 13():848529. PubMed ID: 35529450
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness analysis of vaccination against COVID-19 in China.
    Zhou H; Ding N; Han X; Zhang H; Liu Z; Jia X; Yu J; Zhang W
    Front Public Health; 2023; 11():1037556. PubMed ID: 36960359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Edaravone Dexborneol Downregulates Neutrophil Extracellular Trap Expression and Ameliorates Blood-Brain Barrier Permeability in Acute Ischemic Stroke.
    Huang Y; Zhang X; Zhang C; Xu W; Li W; Feng Z; Zhang X; Zhao K
    Mediators Inflamm; 2022; 2022():3855698. PubMed ID: 36032782
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Edaravone Dexborneol Alleviates Cerebral Ischemic Injury via MKP-1-Mediated Inhibition of MAPKs and Activation of Nrf2.
    Zhang W; Yang H; Gao M; Zhang H; Shi L; Yu X; Zhao R; Song J; Du G
    Biomed Res Int; 2022; 2022():4013707. PubMed ID: 36110124
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-Effectiveness of Coronary and Peripheral Artery Disease Antithrombotic Treatments in Finland.
    Soini E; Virtanen O; Väätäinen S; Briere JB; Bowrin K; Millier A
    Adv Ther; 2020 Jul; 37(7):3348-3369. PubMed ID: 32519113
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of CYP2C19 genotyping to guide antiplatelet therapy for acute minor stroke and high-risk transient ischemic attack.
    Cai Z; Cai D; Wang R; Wang H; Yu Z; Gao F; Liu Y; Kang Y; Wu Z
    Sci Rep; 2021 Apr; 11(1):7383. PubMed ID: 33795788
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Cost-effective analysis of seasonal influenza vaccine in elderly Chinese population].
    Chen C; Liu GE; Wang MJ; Gao TF; Jia HP; Yang H; Feng LZ
    Zhonghua Yu Fang Yi Xue Za Zhi; 2019 Oct; 53(10):993-999. PubMed ID: 31607044
    [No Abstract]   [Full Text] [Related]  

  • 19. Lifetime quality of life and cost consequences of delays in endovascular treatment for acute ischaemic stroke: a cost-effectiveness analysis from a Singapore healthcare perspective.
    Ni W; Kunz WG; Goyal M; Ng YL; Tan K; De Silva DA
    BMJ Open; 2020 Sep; 10(9):e036517. PubMed ID: 32948553
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of endovascular treatment for acute ischemic stroke in China: evidence from Shandong Peninsula.
    Han L; Lan K; Kou D; Meng Z; Feng J; Maitland E; Nicholas S; Wang J
    Health Econ Rev; 2024 Jun; 14(1):37. PubMed ID: 38836982
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.